Palmar Hyperhidrosis Market

DelveInsight’s ‘Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Palmar Hyperhidrosis in the United States.


The Palmar Hyperhidrosis market report provides analysis regarding current treatment practices, an emerging drug, like Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), potential therapies, market share of the individual therapies, historical, current and forecasted Palmar Hyperhidrosis market size from 2017 to 2030 for the United States.


The report also covers current Palmar Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.


Geography Covered

  • The United States

Study Period: 2017–2030


Palmar Hyperhidrosis - Disease Understanding and Treatment Algorithm

Palmar Hyperhidrosis Overview

Palmar hyperhidrosis (PH) is a relatively common condition characterized by excessive hand sweating beyond normal thermoregulatory needs.


Etiologically, the disorder can be primary (idiopathic) or secondary due to an underlying cause. Primary PH tends to arise in childhood or adolescence and usually persists throughout life. Despite its unknown origin, it is attributed to localized sympathetic hyperactivity on otherwise normal eccrine sweat glands, mainly triggered by emotional or thermal stimuli. Secondary PH occurs as a result of underlying pathology or medication use.


Inconvenience is experienced by patients with PH when there is a direct interference with activities involving the hands. Direct interference of sweating impacts work or school life due to difficulties with using computer keyboards, holding objects, working with paper documents, or giving handshakes.


Palmar Hyperhidrosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Palmar Hyperhidrosis market to treat the condition. It also provides the country-wise Palmar Hyperhidrosis treatment guidelines for the United States.


DelveInsight’s Palmar Hyperhidrosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Palmar Hyperhidrosis treatment algorithms and treatment guidelines in the US.


Palmar Hyperhidrosis Epidemiology

The Palmar Hyperhidrosis epidemiology chapters provide insights about historical and current Palmar Hyperhidrosis patient pool and forecasted trends for US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Palmar Hyperhidrosis Palmar Hyperhidrosis epidemiology is segmented by Diagnosed Prevalent Cases of Palmar Hyperhidrosis, Diagnosed cases of Palmar Hyperhidrosis, cases of Palmar Hyperhidrosis by Age, and Severe cases of Palmar Hyperhidrosis. The report includes a thorough analysis of all segmentations.


In the US, the cases of Hyperhidrosis were 15,634,521 in 2017. Moreover, the total diagnosed prevalent cases of Palmar Hyperhidrosis in the United States were found to be 1,407,107 in 2017.


According to DelveInsight’s analysis, In the United States, the highest number of Palmar Hyperhidrosis was reported to be among individuals above 18 years of age.


In the United States, out of all the total prevalent cases reported 773,909 severe and 633,198 non-severe cases for Palmar Hyperhidrosis in 2017.


Palmar Hyperhidrosis Drug Chapters

The drug chapter segment of the Palmar Hyperhidrosis report encloses the detailed analysis of the Palmar Hyperhidrosis pipeline drug. It also helps understand the Palmar Hyperhidrosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.


Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Palmar Hyperhidrosis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), etc. for the treatment of Palmar Hyperhidrosis in the pipeline.


Palmar Hyperhidrosis Market Outlook

The Palmar Hyperhidrosis market size is expected to increase at a significant CAGR during the study period (2017–2030). The United States accounts for the Palmar Hyperhidrosis market size, with USD 246.1 million in 2017.


Palmar Hyperhidrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Palmar Hyperhidrosis market that are expected to get launched in the market during the study period 2017–2030. The analysis covers Palmar Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sale of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of the Palmar Hyperhidrosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.


Palmar Hyperhidrosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Palmar Hyperhidrosis key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of Palmar Hyperhidrosis collaborations, acquisition and merger, licensing, patent details, and other information for Palmar Hyperhidrosis emerging therapies.


Reimbursement Scenario in Palmar Hyperhidrosis

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Palmar HyperhIdrosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.


Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Palmar Hyperhidrosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.


Report Highlights

  • In the coming years, the Palmar Hyperhidrosis market scenario is expected to alter across the USA due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Palmar Hyperhidrosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Palmar Hyperhidrosis Pipeline Analysis
  • Palmar Hyperhidrosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Palmar Hyperhidrosis Report Key Strengths

  • 11 years Forecast
  • The United States
  • Palmar Hyperhidrosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake


Palmar Hyperhidrosis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Palmar Hyperhidrosis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Palmar Hyperhidrosis total market size as well as market size by therapies across the United States during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across the United States, and which country will have the largest Palmar Hyperhidrosis market size during the forecast period (2017–2030)?
  • At what CAGR, the Palmar Hyperhidrosis market is expected to grow in the United States during the forecast period (2017–2030)?
  • What would be the Palmar Hyperhidrosis market outlook across the United States during the forecast period (2017–2030)?
  • What would be the Palmar Hyperhidrosis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Palmar Hyperhidrosis?
  • What is the historical Palmar Hyperhidrosis patient pool in the United States?
  • What would be the forecasted patient pool of Palmar Hyperhidrosis in the United States?
  • What will be the United States' growth opportunities with respect to the patient population pertaining to Palmar Hyperhidrosis?
  • At what CAGR is the population expected to grow in the US during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Palmar Hyperhidrosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Palmar Hyperhidrosis in the USA?
  • What is the Palmar Hyperhidrosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Palmar Hyperhidrosis?
  • How many therapies are developed by each company for Palmar Hyperhidrosis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Palmar hyperhidrosis treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmar hyperhidrosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Palmar hyperhidrosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Palmar hyperhidrosis?
  • What are the global historical and forecasted market of Palmar hyperhidrosis?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Palmar hyperhidrosis market
  • To understand the future market competition in the Palmar hyperhidrosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Palmar hyperhidrosis in the United States.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • To understand the future market competition in the Palmar hyperhidrosis market


What is the forecasted Palmar hyperhidrosis market size in 2030?

DelveInsight estimates an increase in Palmar hyperhidrosis Market Size during the study period, 2017–2030


What are the present Palmar hyperhidrosis market drivers?

Topical Medication, Affecting the larger population and Ease of treatment


What are the Palmar hyperhidrosis market barriers?

Social and Professional Life, Lack of Etiology and Lack of Oral Medication


How many companies are developing drugs for Palmar hyperhidrosis?

Currently, there are many key pharma players engaged in developing the drug for Palmar hyperhidrosis in monotherapy.


Which are the leading companies in the Palmar hyperhidrosis market?

Key Players – Atacama Therapeutics, Dermira Inc


How is epidemiology segmented for Palmar hyperhidrosis?

Prevalent Cases of Palmar hyperhidrosis, Diagnosed cases of Palmar hyperhidrosis, Palmar hyperhidrosis cases by Age and Severity-specific cases Palmar hyperhidrosis.

1. Key Insights

2. Executive Summary of Palmar Hyperhidrosis

3. Competitive Intelligence Analysis for Palmar Hyperhidrosis

4. Palmar Hyperhidrosis: Market Overview at a Glance

4.1. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2017

4.2. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2030

5. Palmar Hyperhidrosis: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Palmar Hyperhidrosis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Palmar Hyperhidrosis Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Palmar Hyperhidrosis Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Palmar Hyperhidrosis Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Palmar Hyperhidrosis Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Palmar Hyperhidrosis Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Palmar Hyperhidrosis Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Palmar Hyperhidrosis Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Palmar Hyperhidrosis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Palmar Hyperhidrosis Treatment and Management

8.2. Palmar Hyperhidrosis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Palmar Hyperhidrosis Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Palmar Hyperhidrosis: Seven Major Market Analysis

13.1. Key Findings

13.2. Palmar Hyperhidrosis Market Size in 7MM

13.3. Palmar Hyperhidrosis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Palmar Hyperhidrosis Total Market Size in the United States

15.1.2. Palmar Hyperhidrosis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Palmar Hyperhidrosis Total Market Size in Germany

15.3.2. Palmar Hyperhidrosis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Palmar Hyperhidrosis Total Market Size in France

15.4.2. Palmar Hyperhidrosis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Palmar Hyperhidrosis Total Market Size in Italy

15.5.2. Palmar Hyperhidrosis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Palmar Hyperhidrosis Total Market Size in Spain

15.6.2. Palmar Hyperhidrosis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Palmar Hyperhidrosis Total Market Size in the United Kingdom

15.7.2. Palmar Hyperhidrosis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Palmar Hyperhidrosis Total Market Size in Japan

15.8.3. Palmar Hyperhidrosis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Palmar Hyperhidrosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1 : 7MM Palmar Hyperhidrosis Epidemiology (2017-2030)

Table 2 : 7MM Palmar Hyperhidrosis Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Palmar Hyperhidrosis Epidemiology in Germany (2017-2030)

Table 6 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Palmar Hyperhidrosis Epidemiology in France (2017-2030)

Table 8 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in France (2017-2030)

Table 9 : Palmar Hyperhidrosis Epidemiology in Italy (2017-2030)

Table 10 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Palmar Hyperhidrosis Epidemiology in Spain (2017-2030)

Table 12 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Palmar Hyperhidrosis Epidemiology in the UK (2017-2030)

Table 14 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Palmar Hyperhidrosis Epidemiology in Japan (2017-2030)

Table 16 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List fo Figure

Figure 1 : 7MM Palmar Hyperhidrosis Epidemiology (2017-2030)

Figure 2 : 7MM Palmar Hyperhidrosis Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Palmar Hyperhidrosis Epidemiology in the United States (2017-2030)

Figure 4 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Palmar Hyperhidrosis Epidemiology in Germany (2017-2030)

Figure 6 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Palmar Hyperhidrosis Epidemiology in France (2017-2030)

Figure 8 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 : Palmar Hyperhidrosis Epidemiology in Italy (2017-2030)

Figure 10 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Palmar Hyperhidrosis Epidemiology in Spain (2017-2030)

Figure 12 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Palmar Hyperhidrosis Epidemiology in the UK (2017-2030)

Figure 14 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Palmar Hyperhidrosis Epidemiology in Japan (2017-2030)

Figure 16 : Palmar Hyperhidrosis Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

Atacama Therapeutics

Dermira, Inc.

  • Tags:
  • Palmar Hyperhidrosis market
  • Palmar Hyperhidrosis market resear...
  • Palmar Hyperhidrosis market insigh...
  • Palmar Hyperhidrosis market trends
  • Palmar Hyperhidrosis market foreca...
  • Palmar Hyperhidrosis market shar

Forward to Friend

Need A Quote